The CEO's open-market buy is a modest but positive signal of insider conviction ahead of the Phase 3 NCP trial. Monitor for trial enrollment updates and any subsequent insider transactions. The small absolute size limits the signal's market impact.
Price Chart
Executive Summary
OKYO Pharma CEO Robert J. Dempsey purchased 15,000 ordinary shares on Nasdaq at $1.54/share, a $23,100 open-market buy. This insider purchase signals management's confidence ahead of a planned Phase 3 pivotal trial for urcosimod in neuropathic corneal pain, but the dollar amount is small relative to a $49M market cap.
Key Facts
- CEO Robert J. Dempsey purchased 15,000 ordinary shares at $1.54/share on Nasdaq on July 23, 2026.
- Total purchase value: $23,100.
- Company plans to initiate a global Phase 3 pivotal trial for urcosimod in neuropathic corneal pain in H2 2026, enrolling ~111 patients.
- Filing is incorporated by reference into the company's F-3 shelf registration (333-293145).
Financial Impact
CEO purchased $23,100 of stock at $1.54/share — small relative to $49M market cap but a clear insider conviction signal.
Risk Factors
- Phase 3 trial failure or delay would negate any insider signal.
- Low cash runway or need for dilutive financing (implied by F-3 shelf reference) could pressure the stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-034316 |
| Exhibit: ex99-1.htm | 0001493152-26-034316 |
| Document: 0001493152-26-034316-index-headers.html | 0001493152-26-034316 |
| Document: 0001493152-26-034316-index.html | 0001493152-26-034316 |
| Document: 0001493152-26-034316.txt | 0001493152-26-034316 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers